Kornimate/medical-research-clean huggingface dataset:
colchicine counteracting inflammation in covid-19 pneumonia

Conditions: Coronavirus Infections; Pneumonia, Viral

Summary: cytokines and chemokines are thought to play an important role in immunity and immunopathology during virus infections \[3\]. patients with severe covid-19 have higher serum levels of pro-inflammatory cytokines (tnf-α, il-1 and il-6) and chemokines (il-8) compared to individuals with mild disease or healthy controls, similar to patients with sars or mers . the change of laboratory parameters, including elevated serum cytokine, chemokine levels, and increased nlr in infected patients are correlated with the severity of the disease and adverse outcome, suggesting a possible role for hyper-inflammatory responses in covid-19 pathogenesis. importantly, previous studies showed that viroporin e, a component of sars-associated coronavirus (sars-cov), forms ca2c-permeable ion channels and activates the nlrp3 inflammasome. in addition, another viroporin 3a was found to induce nlrp3 inflammasome activation . the mechanisms are unclear. colchicine, an old drug used in auto-inflammatory disorders (i.e., familiar mediterranean fever and bechet disease) and in gout, counteracts the assembly of the nlrp3 inflammasome, thereby reducing the release of il-1b and an array of other interleukins, including il-6, that are formed in response to danger signals. recently, colchicine has been successfully used in two cases of life-threatening post-transplant capillary leak syndrome. these patients had required mechanically ventilation for weeks and hemodialysis, before receiving colchicine, which abruptly restored normal respiratory function and diuresis over 48 hrs \[4\].


Eligibility criteria:
inclusion criteria: * positive nasopharyngeal swab for covid-19, asymptomatic or paucisymptomatic, aged ≥70 years and/or with clinical risk factors for poor outcome (clinically relevant chronic lung disease, diabetes and/or heart disease) or * symptomatic with respiratory or systemic symptoms, however clinically stable (mews\ 95% * positive swab for covid-19 * with respiratory and/or systemic symptoms and initial mild respiratory failure e with objective signs of lung involvement; the patient is in stable conditions (mews \ 38°c and or intensive cough, respiratory rate ≥25 /min, or oxygen saturation 94- 95% in room air exclusion criteria: * pregnant or breast feeding * mews \>=3 * hepatic failure child-pugh c * enrollment in other pharmacological studies * ongoing treatment with colchicine * ongoing treatment with antiviral drugs that include ritonavir or cobicistat * any medical condition or disease which in the opinion of the investigator may place the patient at unacceptable risk for study participation.

Keywords: colchicine corona virus infection covid-19
predictive factors and complications of delirium

Conditions: Delirium; Surgery--Complications; Age Problem

Summary: the objective of this research was to determine the incidence, predisposing and triggering factors of delirium following cardiac surgery and its consequences within 30 days of surgery and during a 12-18-month follow-up in older adult patients.

delirium is a transient and fluctuating course syndrome of acute onset that is characterized by reduced level of consciousness, global cognitive dysfunction, and disorder in the sleep-wake cycle. in patients undergoing cardiac surgery, delirium is a complication that affects 2-57% of the patients, reaching as high as 73% in older subjects. the identification of patients at high risk for delirium is important to deliver proper care and avoid the consequences of this complication. however, previous studies published on the subject have not delivered definitive results in the cardiac surgery setting. low educational level has also been studied as a risk factor for delirium after surgery but never in a group of cardiac surgery patients that includes a significant rate of illiteracy. the objective of this research was to determine the incidence, predisposing and triggering factors of delirium following cardiac surgery and its consequences within 30 days of surgery and during a 12-18-month follow-up in older adult patients.

Eligibility criteria:
inclusion criteria: * elective cardiovascular surgery exclusion criteria: * blindness, * deafness, * previous stroke * dementia * delirium at inclusion, preoperatively * creatinine clearance \< 30 ml/min * emergency surgery
hysterectomy and opportunistic salpingectomy

Conditions: Ovarian Cancer; Complication

Summary: hoppsa is a register based randomized controlled trial (r-rct), with the objective to examine if opportunistic salpingectomy compared with no salpingectomy, at the time of hysterectomy for a benign reason * has no increased risk of complications * has no negative side effects on ovarian function and subsequent cardiovascular disease or incidence of fractures * implies reduced risk of subsequent ovarian cancer randomization and follow-up will be conducted within national registers.

high grade serous ovarian cancer, the most fatal subtype, may originate in the fimbriae of the fallopian tubes. this theory has led to the idea of opportunistic salpingectomy as a way of decreasing the risk of epithelial ovarian cancer (eoc). hoppsa is a national register-based rct, with randomization and follow-up in the swedish national quality register of gynecological surgery (gyn/op). hoppsa aims to study if opportunistic salpingectomy is safe, and if it can reduce the risk of eoc. pico p (patients). women \<55 years, undergoing hysterectomy due to a benign reason i (intervention). bilateral salpingectomy at the time of hysterectomy c (comparison). no salpingectomy o (outcomes). primary short term: surgical complications reported according to clavien-dindo at 8 weeks post-operatively intermediate term: change in menopausal symptoms from baseline to 1 year, assessed with menopause rating scale long term: ovarian cancer assessed through the national cancer register recruitment of 4400 patients is estimated to take 4-6 years depending on the participation rate of the swedish gynecological clinics. data retrieval from gynop on short and intermediate term outcomes, requiring smaller sample sizes, will be done at the end of the recruitment period. if these results, ready available when the study recruitment is closed, show that opportunistic salpingectomy does not increase surgical complications and menopausal symptoms, women can be advised to undergo salpingectomy to potentially minimize the future risk of eoc.

Eligibility criteria:
inclusion criteria: * planned hysterectomy for a benign reason * age \< 55 years at randomization * willing to be randomized * vaginal route may be included if the surgeon is confident with performing vaginal salpingectomy. exclusion criteria: * previous bilateral oophorectomy and/or salpingectomy * planned oophorectomy and/or salpingectomy (for reasons such as already diagnosed adnexal tumor, known carrier of the breast cancer susceptibility gene (brca) 1/2 mutation or lynch syndrome (hereditary nonpolyposis colorectal cancer)) * non-understanding of the oral or written study information

Keywords: salpingectomy hysterectomy ovarian cancer
diagnostic criteria in the diagnosis of spinal spondyloarthropathies in patients with chronic low back pain (study p05320)(completed)

Conditions: Spinal Spondyloarthropathies; Axial Spondyloarthritis

Summary: this is a multi-national, multi-site, observational study to determine which of two strategies, when used by referring physicians is superior in the diagnosis of axial spondyloarthritis (as) by rheumatologists.

subjects will be selected using a non-probability sampling method. for each center of excellence, the local network of referring physicians will be assigned, according to a random code in a 1:1 ratio, to use one of the two referral strategies for eligible patients.

Eligibility criteria:
inclusion criteria: * a subject must have back pain of unknown origin, of more than 3 months' duration, and with onset before age 45. * a subject must be willing to give written informed consent and be able to adhere to visit schedules. exclusion criteria: * established diagnosis of spondyloarthropathies at the time of referral. * any clinically significant condition or situation, other than the condition being studied, that, in the opinion of the investigator, would interfere with the study evaluations or optimal participation in the study.
dysautonomia in patients post covid-19 infection

Conditions: Covid19

Summary: the aim for this study is further to elucidate the presence of dysautonomia in post-covid-19 patients, by evaluating heart rate variability.

the covid-19 pandemic is currently a serious global public health concern. this disease is caused by a novel coronavirus which was first discovered in wuhan, china in 2019 and later spread rapidly throughout the world. symptoms of the disease can manifest as fever, cough, encephalitis, myalgia, fatigue, muscle weakness, arthralgia, anosmia, and impairment in other bodily functions in the acute phase. in 17% to 67% of cases, covid-19 patients will develop acute respiratory distress syndrome (ards) and critical illness. besides the impact on the respiratory system, coronaviruses have an effect on other systems including the central nervous system, cardiovascular system, musculoskeletal system, and gastrointestinal system. potential long-term secondary effects on the musculoskeletal system such as muscle weakness, decreased muscle mass, and myopathies have been brought under attention. persisting symptoms in patients recovered from covid-19 infection are frequently a complaint with at least 1 symptom, particularly fatigue and dyspnea. in recent papers, the authors commented on the potential role of dysautonomia in the post-covid-19 entity related to microangiopathy and endothelial injury. such lesions were already reported in brain biopsy samples of severe covid-19. therefore, the aim of this study is further to elucidate the presence of dysautonomia in post-covid-19 patients, by evaluating heart rate variability.

Eligibility criteria:
inclusion criteria: * patients with a diagnosed covid-19 infection that took place 2-8 weeks before study inclusion. * cognitive and language functioning enabling coherent communication between the researcher and the participant. * french-or dutch speaking persons. exclusion criteria: * covid-19 infection \> 8 weeks ago. * the presence of one or more coexisting conditions known to affect hrv analysis (including but not limited to atrial fibrillation, numerous atrial or ventricular extra beats, paced rhythm, left ventricular bundle branch block, cancer, kidney or hepatic failure, and diabetes mellitus)
phase i/ii, open-label, multi-center, two part dose-escalation, safety, pharmacokinetics (pk) and efficacy study of azd4877 in patients with acute myelogenous leukemia (aml)

Conditions: Acute Myelogenous Leukemia

Summary: the primary purpose of this study is to find out what the maximum tolerated dose is for an experimental drug called azd4877 based on the side effects experienced by patients that receive azd4877 on a daily times 3 schedule in acute myelogenous leukemia (aml). for enrollment information see the central contact information below


Eligibility criteria:
inclusion criteria: * part a: relapsed or refractory leukemia for which no standard therapies are anticipated to result in a durable remission * part b: aml who have had no more than two prior relapses or failed to achieve remission after at least one induction treatment. * patients with prior allogeneic transplants who remain clinically stable for ≥2 weeks or more off immunosuppressive therapy exclusion criteria: * promyelocytic acute myelogenous leukemia * prior allogeneic transplant requiring immunosuppressive therapy or treating physician does not consider patient to be a candidate for allogeneic transplantation. * liver injury

Keywords: phase i phase ii acute myelogenous leukemia aml cancer
aly688-sr in generally healthy overweight or obese adults

Conditions: Overweight and Obesity

Summary: first in human study of aly688-sr administered as a subcutaneous injection

the study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single ascending doses of aly688-sr compared to placebo administered as a subcutaneous injection.

Eligibility criteria:
inclusion criteria: * body mass index 24 to 35 kg/m2 body weight 60 to 120 kg, exclusion criteria: * confirmed diabetes on treatment inadequately managed hypertension poorly controlled hypercholesterolemia
ivermectin role in covid-19 clinical trial

Conditions: Covid19

Summary: because ivermectin is being used to treat covid-19 with insufficient evidence, the investigator conducted a randomized clinical trial to investigate the efficacy and safety of ivermectin in comparison to hydroxychloroquine and placebo in severe covid-19 patients. the study was conducted in shebin-elkom teaching hospital and recruited patients from december 6, 2020, to january 31, 2021.

this study is an adaptive, randomized, double-blinded, controlled trial to evaluate the safety and efficacy of therapeutic agents in hospitalized adult patients diagnosed with covid-19. the study is a single-center trial that will be conducted in shebin elkom teaching hospital. the study will be a series of 3-arm comparisons between two different investigational therapeutic agents (ivermectin and hydroxychloroquine) and a placebo. there will be interim monitoring to allow early stopping for futility, efficacy, or safety. because of the possibility that background standards of supportive care may evolve/improve over time as more is learned about the successful management of covid-19, comparisons of safety and efficacy will be based on data from concurrently randomized participants. an independent data and safety monitoring board (dsmb) will actively monitor interim data to make recommendations about early study closure or changes to study arms.

Eligibility criteria:
inclusion criteria: 1. subject (or legally authorized representative) provides written informed consent prior to initiation of any study procedures. 2. understands and agrees to comply with planned study procedures. 3. agrees to the collection of op swabs and venous blood per protocol. 4. male or non-pregnant female adult ≥18 years of age at time of enrollment. 5. has laboratory-confirmed sars-cov-2 infection as determined by pcr, or other 6. severe cases according to who definition. exclusion criteria: 1. alt/ast \> 5 times the upper limit of normal. 2. mortality within 12 hours of admission. 3. pregnancy. 4. anticipated transfer to another hospital within 24 hours. 5. allergy to any study medication commercial or public health assay in any specimen prior to randomization. 6. mechanically ventilated on admission
hiv study on measuring the reservoir on cellular level to cure infection

Conditions: Hiv

Summary: the aim of this study is to gain new insights into hiv latency and reversal through extensive blood and tissues sampling (lymph node and colon biopsies) from 25 individuals under art.


Eligibility criteria:
inclusion criteria: * documented hiv-1 subtype b infection * able and willing to provide written informed consent * age = or \>18 years and \< 65 years * cd4 count at screening \> 350/μl * viral load \< 40 copies/ml determined by cobastaqman hiv-1 test v2.0 assay for at least 2 years (one blip \< 200 copies/ml is allowed) * ability and willingness to have blood and tissue samples collected and stored for 20 years and used for various research purposes. exclusion criteria: * previous or current history of opportunistic infection (aids defining events as defined in category c of the cdc clinical classification), consisting of chronic hiv-1 infection. * evidence of active hbv infection (hepatitis b surface antigen positive or hbv viral load positive in the past and no evidence of subsequent seroconversion (=hbv antigen or viral load negative and positive hbv surface antibody)). * evidence of active hcv infection: hcv antibody positive result within 60 days prior to study entry with positive hcv viral load or, if the hcv antibody result is negative, a positive hcv rna result within 60 days prior to study entry. * current or known history of cardiomyopathy or significant ischemic or cerebrovascular disease. * current or known history of cancer. * history of hiv-related thrombocytopenia. * pregnancy or breastfeeding. * any conditions, including preexisting psychiatric and psychological disorders, which will in the opinion of the investigator interfere with the trial conduct or safety of the participant. * previous participation in a trial evaluating an immune modulating agent. * abnormal results of standard of care laboratory tests: 1. confirmed haemoglobin \<11g/dl for women and \<12 g/dl for men 2. confirmed platelet count \<100 000/µl \* 3. confirmed neutrophil count \<1000/μl 4. confirmed ast and/or alt \>10xuln * active drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements. * acute or serious illness, in the opinion of the site investigator, requiring systemic treatment and/or hospitalization within 60 days prior to entry. * the following treatment will be prohibited three months before screening and during the study: 1. immunosuppressive drugs (inclusive corticosteroids) except for drugs used for topical use. 2. immunomodulatory drugs including but not limited to granulocyte-colony stimulating factors, granulocyte-monocyte colony-stimulating factor, interleukin 2, 7 \& 15.

Keywords: hiv latency latency reversing agents latency reversal
exploring the relationship between varying co2 levels and the regional bold signal, by using breathing exercises

Conditions: Healthy

Summary: the purpose of this study is to explore how arterial paco2 effect regional blood oxygen level dependent (bold) signal, and indirectly the brain regional o2 level .

among many parameters effecting cerebral blood flow(cbf), partial pressure of co2 (paco2) in arterial blood has a significant effect. a small increase in arterial paco2 level will cause a significant increase of cbf , followed by increase of o2 level . the main objective is to explore the effect of arterial paco2 level on regional cbf and brain o2 level, by using breathing exercises to modulate arterial paco2. the regional blood oxygen level dependent (bold) signal produced by mri , will indicate the regional o2 level.

Eligibility criteria:
inclusion criteria: * adults over 18 years old . exclusion criteria: * under 18 years old. * artificial pacemaker * implantable cardioverter-defibrillator (icd) * hearing aid, implantable or portable. * artificial heart valve * surgical clips * metal fragments in eyes * electronic stimulators * implanted pumps * implantable neurostimulation device * metal fragments of any sort * permanent makeup or tattoo * transfusion pump * pregnant or breast feeding women * false teeth , retainer or dental crown

Keywords: regional bold signal dependency on arterial paco2. effect of breathing exercises on brain regional o2 level. healthy subjects
genetics and shared decision making in improving care for patients with stage iva-c non-small cell lung cancer

Conditions: Activating ALK Gene Mutation Negative; Activating EGFR Gene Mutation Negative; Activating ROS1 Gene Mutation Negative; Health Care Provider; Lung Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8

Summary: this trial studies the use of genetics and shared decision making in improving care for patients with stage iva-c non-small cell lung cancer. developing educational tools may help patients with non-small cell lung cancer to increase patient treatment knowledge, reduce decisional conflict, and promote treatment shared decision making with their health care providers.

primary objectives: i. use the information on genomic tumor diagnostics, provider treatment recommendations, and patient and provider feedback on the treatment decision making process, which will be used to develop materials and methods to adapt an existing decision counseling program (dcp) for use with patients diagnosed with advanced non-small cell lung carcinoma (nsclc) as a standard component of clinical care. secondary objectives: i. pilot test the adapted dcp in a subset of patients to determine the feasibility of delivering the dcp session. ii. assess dcp effects on patient treatment knowledge and decisional conflict. iii. assess treatment choice. outline: phase i: use physician input to develop draft treatment education materials and use patient input to adapt an online decision counseling application for use in helping patients clarify treatment preference. phase ii: patients complete a treatment decision counseling session/interview about genetic testing and supportive/palliative care with a qualified member of the research team in-person or via telephone. health care providers receive a 1-page summary of session results for use in treatment shared decision making at the next office visit. after completion of study, participants are followed up at 30 and 60 days.

Eligibility criteria:
inclusion criteria: * newly diagnosed with advanced nsclc (stage iv a-c) that are wild-type for activating genetic alterations (egfr, ros 1, and alk). * may or may not be candidates for immune checkpoint therapy. * may have had 1-any number of prior systemic therapy regimens. * if prior systemic regimen, must have progression disease at time of evaluation. * untreated brain metastases permitted. * completed pathological analysis of tumor tissue. * patients who have exhausted targeting therapy options. * can speak and read english. * all participants must be willing to comply with all study procedures and be available for the duration of the study. * providers: those who treat nsclc patients as described above. exclusion criteria: • there are no specific exclusions in this trial for particular medical conditions, comorbidities, or performance status. any patient deemed appropriate to be considered for evaluation and/or treatment would be appropriate to include in this trial.
matrix metalloproteinases's in oral biofluids during pregnancy and postpartum

Conditions: Pregnancy

Summary: the aim of this study was to investigate salivary and gingival crevicular fluid (gcf) levels of mmp-8, mmp-9 and timp-1 during 2/3 trimester of pregnancy and after delivery

mmp-8 and mmp-9 have been reported to reflect the inflammatory status in periodontal tissues and, therefore represent as potential biomarkers of periodontitis. the balance between tissue inhibitors of metalloproteinases (timps) and mmps play an important role in maintaining the integrity of healthy periodontium.

Eligibility criteria:
inclusion criteria: * pregnant group included women, who were in their second trimester (weeks 16-24) and third trimester (weeks 25-34) exclusion criteria: * (a) any known systemic disease, (b) periodontal treatment within the last six months, (c) patients having less than 10 teeth, (d) smokers and (e) individuals with bmi \> 30 kg/m2

Keywords: gingivitis saliva gingival crevicular fluid